Abstract 2106P
Background
Vaccination against SARS-CoV-2 reduces morbidity from COVID-19 infection in patients (pts) with cancer. Hesitancy toward vaccination remains in some groups. Ongoing vaccinations are recommended for vulnerable pts. This study provides detailed patient-reported and safety outcomes, providing information for patients and clinicians regarding vaccination safety.
Methods
SerOzNET is a prospective study of pts with cancer who received COVID-19 vaccination (BNT162b2, mRNA1273 or ChadOx1-S) in 2021-22 in 3 cohorts: children (5-11 years(y)), adolescents (12-19y) and adults. From pre-vaccination (to 1 month post dose 3, pts completed serial electronic surveys: Oxford COVID-19 Vaccine Confidence and Complacency Scale, patient reported adverse events (AE), and quality of life (5-19y: PedsQL; 20+:QLQC30). Physicians reported safety, including serious adverse events and thrombosis.
Results
511 pts were enrolled (40 children, 74 adolescents, 397 adults); 499 had one or more patient or medical outcome report completed. Median age was 52 (range 5-85). Pain at injection site was the commonest AE (60-90% of pts). AEs reported in 20-50% of all pts after dose 1, 2 or 3 were fatigue, muscle pain and fever. Headache was more common in adolescents and adults (18-26%) than children (0-11%). Chills were more common in children and adolescents (11-29%) than adults (12-19%). Delays/modifications to cancer treatment from dose 1 to 1 month post dose 2 were reported in 33% of children, 27% of adolescents and 21% of adults; and from dose 3 to 1 month post dose 3 in 10% of children, 18% of adolescents and 12% of adults. None were attributed to vaccine toxicity. Venous thromboembolic events (VTE) were reported in 4/397 adults; there were no arterial events, and no thrombotic events in children or adolescents. No allergic reactions were reported. Mean QLQC30 in adults, and PedsQL in pts <20y was similar pre and post dose 1 (p=n.s. all ages) and 2 (p=n.s. children, adults. Adolescents: 2% improvement, p=0.006).
Conclusions
This large trial dataset demonstrates SARS-CoV-2 vaccination in pts with cancer has manageable toxicity. VTE was low, consistent with background rates. Individuals with cancer can be reassured that SARS-CoV-2 vaccination is safe and will not disrupt their cancer therapy.
Clinical trial identification
ACTRN12621001004853.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Cancer Australia (Australian Government), Victorian Cancer Agency (Victorian Government, Australia), Leukaemia Foundation Australia.
Disclosure
E.S. Ahern: Financial Interests, Institutional, Funding, Research funding: Amgen. All other authors have declared no conflicts of interest.
Resources from the same session
2045P - Patient Reported Outcome Measures (PROMs) capturing therapy adherence of cancer patients: A systematic literature review
Presenter: Luise Richter
Session: Poster session 06
2046P - The importance of communicating bad news in medical education
Presenter: Georgios Goumas
Session: Poster session 06
2047P - Neutrop: A descriptive, observational study for G-CSF prescription in daily practice
Presenter: Florian Scotté
Session: Poster session 06
2048P - Frequency and clinical relevance of drug-drug interactions with oxycodone among patients with cancer
Presenter: Lotte Hulskotte
Session: Poster session 06
2049P - Osimertinib-related muscle cramps as a common adverse event: A real-world data analysis in the post-approval setting
Presenter: Gisele Moreira
Session: Poster session 06
2050P - Integrating ayurveda herbs with standard of care for management of cancer or cancer treatment related anorexia
Presenter: Yogesh Bendale
Session: Poster session 06
2051P - E-PRO within comprehensive companion program for patients undergoing systemic cancer treatment to reduce emergency visits and inpatient admission in a Peruvian institution
Presenter: Patricia Rioja Viera
Session: Poster session 06
2052P - Adverse events in FLOT chemotherapy for locally advanced gastric cancer: An observational study of pre- and post-operative toxicity profiles
Presenter: Camila Oliveira
Session: Poster session 06
2053P - Dehospitalization through outpatient drug release in clinical pharmacy as a strategic cost-minimization action in a public oncology hospital in the Eastern Amazon: A quantitative analysis
Presenter: Kalysta Borges
Session: Poster session 06
2054P - Metastatic cancer patients hospitalized at initial diagnosis: When does rescue systemic therapy make sense? ONIRIS - A national, prospective study
Presenter: Colin Vercueil
Session: Poster session 06